Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

novel approach to test the toxicity of cancer drugs.

2.

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

3.

Novel biomarkers may improve diagnosis of gallbladder cancer

4.

Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma

5.

Pancreatic cancer RNA vaccine shows durable T cell immunity


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot